Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

Abstract Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptors agonist, has demonstrated efficacy in the treatment of patients with an acute exacerbation of schizophrenia in a 4-week, double-blind, placebo-controlled study. The aim of this 26-week open-label extension...

Full description

Bibliographic Details
Main Authors: Christoph U. Correll, Kenneth S. Koblan, Seth C. Hopkins, Yan Li, Heather Dworak, Robert Goldman, Antony Loebel
Format: Article
Language:English
Published: Nature Portfolio 2021-12-01
Series:npj Schizophrenia
Online Access:https://doi.org/10.1038/s41537-021-00190-z

Internet

https://doi.org/10.1038/s41537-021-00190-z

Similar Items